Moomoo AI 已提取核心訊息
Shattuck Labs, Inc., a clinical-stage biotechnology company, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on January 24, 2024. The Austin, Texas-based company, incorporated in Delaware, is registering 3,100,823 shares of common stock for resale, which are issuable upon the exercise of pre-funded warrants acquired by the selling stockholders under a securities purchase agreement dated December 21, 2023. The pre-funded warrants have an exercise price of $0.0001 per share. Shattuck Labs will not receive any proceeds from the sale of shares by the selling stockholders, except for the nominal exercise price upon the cash exercise of the warrants, which will be used for general corporate purposes. The shares may be sold by the selling stockholders from...Show More
Shattuck Labs, Inc., a clinical-stage biotechnology company, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on January 24, 2024. The Austin, Texas-based company, incorporated in Delaware, is registering 3,100,823 shares of common stock for resale, which are issuable upon the exercise of pre-funded warrants acquired by the selling stockholders under a securities purchase agreement dated December 21, 2023. The pre-funded warrants have an exercise price of $0.0001 per share. Shattuck Labs will not receive any proceeds from the sale of shares by the selling stockholders, except for the nominal exercise price upon the cash exercise of the warrants, which will be used for general corporate purposes. The shares may be sold by the selling stockholders from time to time after the registration statement becomes effective, through various methods described in the 'Plan of Distribution' section. Shattuck Labs' common stock is listed on The Nasdaq Global Select Market under the symbol 'STTK'. As of January 23, 2024, the last reported sale price of Shattuck's common stock was $9.52 per share. The registration statement includes details about the selling stockholders, the use of proceeds, risk factors, and legal matters related to the offering.
臨床階段的生物技術公司Shattuck Labs, Inc. 已於2024年1月24日向美國證券交易委員會（SEC）提交了S-3表格註冊聲明。這家總部位於德克薩斯州奧斯汀的公司在特拉華州註冊成立，註冊了3,100,823股普通股進行轉售，這些普通股可在行使賣方股東根據2023年12月21日的證券購買協議收購的預先注資認股權證後發行。預先注資的認股權證的行使價爲每股0.0001美元。Shattuck Labs不會從出售股東出售股票中獲得任何收益，但認股權證現金行使時的名義行使價除外，該權證將用於一般公司用途。註冊聲明生效後，賣出股東可以通過 “分配計劃” 部分中描述的各種方法不時出售股票。Shattuck Labs的普通股在納斯達克全球精選市場上市，股票代碼爲 “STTK”。截至2024年1月23日，沙特克普通股最新公佈的銷售價格爲每股9.52美元。註冊聲明包括有關出售股東、所得款項用途、風險因素以及與發行相關的法律事務的詳細信息。
臨床階段的生物技術公司Shattuck Labs, Inc. 已於2024年1月24日向美國證券交易委員會（SEC）提交了S-3表格註冊聲明。這家總部位於德克薩斯州奧斯汀的公司在特拉華州註冊成立，註冊了3,100,823股普通股進行轉售，這些普通股可在行使賣方股東根據2023年12月21日的證券購買協議收購的預先注資認股權證後發行。預先注資的認股權證的行使價爲每股0.0001美元。Shattuck Labs不會從出售股東出售股票中獲得任何收益，但認股權證現金行使時的名義行使價除外，該權證將用於一般公司用途。註冊聲明生效後，賣出股東可以通過 “分配計劃” 部分中描述的各種方法不時出售股票。Shattuck Labs的普通股在納斯達克全球精選市場上市，股票代碼爲 “STTK”。截至2024年1月23日，沙特克普通股最新公佈的銷售價格爲每股9.52美元。註冊聲明包括有關出售股東、所得款項用途、風險因素以及與發行相關的法律事務的詳細信息。
有用
沒用